Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Tens of thousands of Kaiser Permanente workers in California and Hawaii have gone on strike, demanding safer staffing levels ...

From left to right: Moderator Michael Kalishman, chief venture officer, Sentara Health; Nick Culbertson, managing director, Techstars; Dr. Ngoc-Anh Nguyen, vice chair of research, Houston Methodist ...

Kailera Therapeutics executives say their lead drug candidate could become best in a category of obesity drugs currently led by a blockbuster Eli Lilly product, and the biotech has secured $600 ...

Insurers are cutting coverage for costly GLP-1 weight loss drugs, sparking backlash from advocates who say they're vital for ...

Interoperability doesn’t start with a 9-1-1 call. It begins with a commitment to data quality, documentation integrity, and adherence to national standards across the system. For EMS, this means ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

The U.S. has a lower life expectancy and higher rate of premature death than any other wealthy country. This is despite the fact that we spend nearly twice as much per capita on healthcare. Exorbitant ...

Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in ...

DUOS, a technology-enabled service provider, has raised $130 million to expand its platform to more health plans across the country, it announced on Thursday. The Minneapolis-based company supports ...

Experts warn that the Trump administration’s new $100,000 fee for H-1B visa applications could worsen healthcare’s workforce ...